You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 2, 2025

Drug Sales Trends for LATUDA


✉ Email this page to a colleague

« Back to Dashboard


Payment Methods and Pharmacy Types for LATUDA (2021)

Revenues by Pharmacy Type

Pharmacy Type Revenues
MAIL-ORDER $138,167,303
INSIDE ANOTHER STORE $1,109,421,860
[disabled in preview] $2,298,719,337
This preview shows a limited data set
Subscribe for full access, or try a Trial

Units Sold by Pharmacy Type

Pharmacy Type Units
MAIL-ORDER 155,996
INSIDE ANOTHER STORE 748,486
[disabled in preview] 1,186,818
This preview shows a limited data set
Subscribe for full access, or try a Trial

Revenues by Payment Method

Payment Method Revenues
MEDICAID $645,286,979
MEDICARE $1,369,035,783
[disabled in preview] $1,531,985,738
This preview shows a limited data set
Subscribe for full access, or try a Trial
Drug Sales Revenue Trends for LATUDA
Drug Units Sold Trends for LATUDA

LATUDA Market Analysis and Financial Projection

Market Analysis and Sales Projections for LATUDA

Overview of LATUDA

LATUDA, also known as lurasidone hydrochloride, is an oral atypical antipsychotic belonging to the chemical class of benzisothiazol derivatives. It is approved for the treatment of schizophrenia and bipolar depression in various regions, including the United States, Japan, and the European Union[1][4].

Mechanism of Action and Dosage

LATUDA works by altering the chemical effects in the brain, primarily through its activity as a parent drug. The recommended starting dose for adults is 40 mg once daily, with a maximum recommended dose of 160 mg/day. For adolescents (13-17 years), the starting dose is also 40 mg once daily, with a maximum dose of 80 mg/day[4].

Market Insights

Current Market Scenario

The current market for LATUDA is influenced by several factors, including regulatory milestones, research and development activities, and the emergence of new therapies. In the United States and Japan, LATUDA is approved for both schizophrenia and bipolar depression, while in the EU, it is only approved for schizophrenia[1][4].

Regulatory Milestones

The FDA has tentatively approved a generic version of LATUDA in the US, although the generic versions are not currently available due to agreements between generic drug makers and the manufacturer. This has significant implications for the market dynamics, as the introduction of generics can impact the sales of the branded drug[1].

Research and Development

The ongoing research and development activities for LATUDA include clinical trials and the assessment of new therapeutic approaches. These activities are crucial for understanding the drug's potential in different patient populations and for identifying future market opportunities[4].

Sales Projections

Global Market Forecast

The global market for lurasidone is expected to grow, driven by increasing healthcare spending and the need for effective treatments for schizophrenia and bipolar depression. From 2023 to 2032, the market is projected to expand significantly, with a compound annual growth rate (CAGR) that reflects the growing demand for antipsychotic medications[2].

Regional Market Analysis

  • United States: The market size for LATUDA in the US is expected to grow, driven by its approvals for both schizophrenia and bipolar depression. The forecasted sales data from 2023 to 2032 will be crucial for decision-making regarding therapeutic portfolios[1][4].
  • Japan: Despite a temporary decrease in revenue due to the end of exclusivity sales period and changes in the payer mix, sales of LATUDA in Japan are expected to increase in the coming years[5].
  • Europe: In the EU4 (Germany, France, Italy, and Spain) and the UK, the market for LATUDA is also set to change due to extensive research and incremental healthcare spending. The launch of late-stage emerging therapies will significantly impact the market[4].

Competitive Landscape

The competitive landscape for LATUDA includes both marketed therapies and late-stage emerging therapies. Other emerging products for schizophrenia and bipolar depression are expected to provide tough market competition, influencing LATUDA's dominance in the market[1][4].

SWOT Analysis and Analyst Views

The SWOT analysis for LATUDA highlights its strengths, such as its efficacy in treating schizophrenia and bipolar depression, and its weaknesses, including the potential impact of generic versions. Analyst views suggest that the market scenario for LATUDA will change due to extensive research and incremental healthcare spending, enabling drug manufacturers to penetrate the market more effectively[1][4].

Emerging Therapies

The launch of late-stage emerging therapies for schizophrenia and bipolar depression will significantly impact the market for LATUDA. These new therapies focus on novel approaches to treat and improve disease conditions, presenting both challenges and opportunities for LATUDA's market position[1][4].

Financial Projections

In terms of financial projections, the revenue from LATUDA is expected to decrease in the short term due to the loss of exclusivity and changes in the payer mix. However, long-term projections indicate growth, particularly as sales collaborations and new market strategies are implemented. For example, in North America, despite the loss of exclusivity for LATUDA, other products like ORGOVYX® and MYFEMBREE® are expected to drive growth[5].

Key Takeaways

  • Market Growth: The global market for LATUDA is expected to grow driven by increasing healthcare spending and the need for effective treatments.
  • Regulatory Impact: The tentative approval of generic versions and the end of exclusivity periods will impact sales.
  • Competitive Landscape: Emerging therapies will provide significant competition to LATUDA.
  • Regional Variations: Market performance will vary by region, with the US, Japan, and Europe showing different trends.
  • Financial Projections: Short-term revenue decreases are expected, but long-term growth is anticipated.

FAQs

What is LATUDA used for?

LATUDA (lurasidone hydrochloride) is used for the treatment of schizophrenia and bipolar depression in various patient populations, including adolescents and adults.

What is the recommended dosage for LATUDA?

The recommended starting dose for adults is 40 mg once daily, with a maximum dose of 160 mg/day. For adolescents (13-17 years), the starting dose is also 40 mg once daily, with a maximum dose of 80 mg/day.

Has a generic version of LATUDA been approved?

Yes, the FDA has tentatively approved a generic version of LATUDA, although it is not currently available due to agreements between generic drug makers and the manufacturer.

How will the market for LATUDA change in the coming years?

The market for LATUDA is expected to change due to extensive research, incremental healthcare spending, and the launch of late-stage emerging therapies. These factors will expand the market size and enable drug manufacturers to penetrate more into the market.

What are the key regions for LATUDA sales?

The key regions for LATUDA sales include the United States, Japan, and Europe (specifically EU4 and the UK).

Sources

  1. Research and Markets: "LATUDA Market Drug Insight and Market Forecast - 2032" report.
  2. Cognitive Market Research: "Lurasidone Market Report 2024 (Global Edition)".
  3. Business Wire: "Research and Markets: Latuda - Analysis and Forecasts from 2011 to 2020".
  4. PR Newswire: "LATUDA Drug Insight and Market Forecast - 2032".
  5. Sumitomo Pharma: "Investors Meeting Presentation for FY2022".

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.